Nicholas M Donin1, Sanjay Mohan2, Hai Pham2, Hersh Chandarana3, Ankur Doshi3, Fang-Ming Deng4, Michael D Stifelman2, Samir S Taneja2, William C Huang2. 1. Department of Urology, New York University School of Medicine, New York, NY. Electronic address: Nicholas.Donin@nyumc.org. 2. Department of Urology, New York University School of Medicine, New York, NY. 3. Department of Radiology, New York University School of Medicine, New York, NY. 4. Department of Pathology, New York University School of Medicine, New York, NY.
Abstract
BACKGROUND: The purpose of this study was to describe the clinicopathologic characteristics and oncologic outcomes of patients who underwent nephrectomy for cystic renal masses. PATIENTS AND METHODS: Using an institutional review board-approved database, we retrospectively reviewed the clinical, pathologic, radiologic, and oncologic outcome data of patients who received nephrectomy for a complex cystic renal mass. RESULTS: Sixty-one patients were identified who received nephrectomy for a complex cystic lesion. Average age was 64 years. Thirty-nine (64%) patients were male. At the time of resection, 1 (1.6%), 3 (4.8%), 53 (86.8%), and 4 (6.5%) had a Bosniak category II, IIF, III, and IV cystic lesion, respectively. Nineteen (31.1%) patients were initially managed expectantly but underwent surgery because of progression of complexity on follow-up. Mean pathologic tumor size was 3.3 cm (range, 0.7-12 cm). Forty-eight (78.6%) of the lesions were found to be malignant. Thirty-seven (77.1%), 5 (10.4%), 4 (8.3%), and 2 (4.1%) were stage T1a, T1b, T2a, and T3a, respectively. Clear cell was the most common histologic subtype (44%), followed by papillary (21.3%), and unclassified RCC (4.9%). With a mean and median follow-up of 48.4 and 43.0 months, respectively, no patients developed a local or metastatic recurrence. All patients were alive at last follow-up. CONCLUSION: In our series with moderate follow-up, cystic RCCs do not appear to recur or progress regardless of size, histologic subtype, or grade. These findings suggest the malignant potential of cRCCs is significantly less than solid RCCs. Further investigation is required to determine if cRCCs should be classified and managed independently from solid RCCs.
BACKGROUND: The purpose of this study was to describe the clinicopathologic characteristics and oncologic outcomes of patients who underwent nephrectomy for cystic renal masses. PATIENTS AND METHODS: Using an institutional review board-approved database, we retrospectively reviewed the clinical, pathologic, radiologic, and oncologic outcome data of patients who received nephrectomy for a complex cystic renal mass. RESULTS: Sixty-one patients were identified who received nephrectomy for a complex cystic lesion. Average age was 64 years. Thirty-nine (64%) patients were male. At the time of resection, 1 (1.6%), 3 (4.8%), 53 (86.8%), and 4 (6.5%) had a Bosniak category II, IIF, III, and IV cystic lesion, respectively. Nineteen (31.1%) patients were initially managed expectantly but underwent surgery because of progression of complexity on follow-up. Mean pathologic tumor size was 3.3 cm (range, 0.7-12 cm). Forty-eight (78.6%) of the lesions were found to be malignant. Thirty-seven (77.1%), 5 (10.4%), 4 (8.3%), and 2 (4.1%) were stage T1a, T1b, T2a, and T3a, respectively. Clear cell was the most common histologic subtype (44%), followed by papillary (21.3%), and unclassified RCC (4.9%). With a mean and median follow-up of 48.4 and 43.0 months, respectively, no patients developed a local or metastatic recurrence. All patients were alive at last follow-up. CONCLUSION: In our series with moderate follow-up, cystic RCCs do not appear to recur or progress regardless of size, histologic subtype, or grade. These findings suggest the malignant potential of cRCCs is significantly less than solid RCCs. Further investigation is required to determine if cRCCs should be classified and managed independently from solid RCCs.
Authors: Brian R Winters; John L Gore; Sarah K Holt; Jonathan D Harper; Daniel W Lin; Jonathan L Wright Journal: Urol Oncol Date: 2015-08-28 Impact factor: 3.498
Authors: Patrick O Richard; Philippe D Violette; Michael A S Jewett; Frederic Pouliot; Michael Leveridge; Alan So; Thomas F Whelan; Ricardo Rendon; Antonio Finelli Journal: Can Urol Assoc J Date: 2017-03-16 Impact factor: 1.862
Authors: Joel Prince; Eric Bultman; Louis Hinshaw; Anna Drewry; Michael Blute; Sara Best; Fred T Lee; Timothy Ziemlewicz; Meghan Lubner; Fangfang Shi; Stephen Y Nakada; E Jason Abel Journal: J Urol Date: 2014-12-11 Impact factor: 7.450
Authors: David Castañeda-Millán; Darwin Barros-Valderrama; Diego Camacho-Nieto; Carlos A Riveros; Juan Alzate-Granados; Javier Salgado-Tovar; Wilfredo Donoso-Donoso Journal: Cureus Date: 2019-11-29
Authors: Félix Couture; Antonio Finelli; Amélie Tétu; Bimal Bhindi; Rodney H Breau; Anil Kapoor; Wassim Kassouf; Luke Lavallée; Simon Tanguay; Philippe D Violette; Patrick O Richard Journal: BMC Urol Date: 2020-04-28 Impact factor: 2.264